Neoadjuvant Treatment Versus Upfront Surgery in Resectable Pancreatic Cancer: A Cost-Effectiveness Analysis.

Arjani, Simran; Prasath, Vishnu; Suri, Nipun; Li, Sharon; Ahlawat, Sushil; Chokshi, Ravi J

Arjani, Simran; Prasath, Vishnu; Suri, Nipun; Li, Sharon; Ahlawat, Sushil; Chokshi, Ravi J.

Afiliação

Arjani S; Rutgers New Jersey Medical School, Newark, NJ.
Prasath V; Rutgers New Jersey Medical School, Newark, NJ.
Suri N; Department of Internal Medicine, Rutgers New Jersey Medical School, Newark, NJ.
Li S; Division of Hematology/Oncology, Department of Internal Medicine, Rutgers New Jersey Medical School, Newark, NJ.
Ahlawat S; Division of Gastroenterology & Hepatology, Department of Internal Medicine, Rutgers New Jersey Medical School, Newark, NJ.
Chokshi RJ; Division of Surgical Oncology, Department of Surgery, Rutgers New Jersey Medical School, Newark, NJ.

JCO Oncol Pract ; 19(3): e439-e448, 2023 03.

Article em En | MEDLINE | ID: mdl-36548928

Assuntos

Adenocarcinoma; Neoplasias Pancreáticas; Idoso; Estados Unidos; Humanos; Neoplasias Pancreáticas/patologia; Terapia Neoadjuvante/métodos; Análise de Custo-Efetividade; Medicare; Neoplasias Pancreáticas

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Adenocarcinoma Tipo de estudo: Health_economic_evaluation / Prognostic_studies Limite: Aged / Humans País/Região como assunto: America do norte Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google